Over the past several weeks, headlines have warned that the U.S. Food and Drug Administration is moving to shut down compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy. If you have been getting a lower-cost compounded semaglutide through a telehealth platform, the news has probably raised an urgent question: will this still be available? This article walks through what is actually happening, what the evidence does and does not support, and how to tell a legitimate treatment pathway from one worth avoiding. The Peptide Foundation is independent. It sells nothing and prescribes nothing. Our only job is to explain the landscape honestly.
What the FDA Actually Did
Compounding pharmacies are permitted to make copies of a brand-name drug in larger volumes when that drug is on the FDA's official shortage list. Semaglutide landed on that list during a period of intense demand, which is how compounded versions became widely available through telehealth. The FDA has since determined that the brand-name product is no longer in shortage. Removing a drug from the shortage list is the regulatory trigger that ends most large-scale compounding of it. In plain terms, the legal opening that allowed widespread compounded semaglutide is closing.
Regulation Is Not the Same as the Evidence Base
It helps to separate two very different questions. One is what the semaglutide molecule has been studied for. The other is whether a compounded version of it should keep being mass-produced. These are not the same debate. Semaglutide has one of the larger clinical-trial records among drugs studied for weight management. In a large randomized trial, once-weekly semaglutide was associated with a mean 14.9 percent reduction in body weight over 68 weeks, compared with 2.4 percent for placebo. A separate trial reported that participants who continued treatment tended to sustain their reduction, while those switched to placebo tended to regain weight. Longer-term follow-up has reported weight reduction maintained for up to four years. That research describes FDA-approved products studied in trial populations. It reports averages and probabilities, not a promise about any individual outcome, and results outside a trial can differ.
The FDA's concern with compounding is not that the molecule lacks an evidence base. It is that compounded products are not subject to the same batch-level checks for sterility, potency, and dosing accuracy that govern an FDA-approved drug. There have been documented reports of dosing errors tied to confusing labeling or improper preparation. That is a real, if minority, safety issue, and it is the heart of the regulatory case.
503A, 503B, and Research-Use-Only Products
Not all compounding is the same, and the distinction matters a great deal. A 503A pharmacy prepares a compounded medication for a specific patient with a prescription. A 503B outsourcing facility makes larger batches under stricter FDA oversight. Both operate inside the licensed pharmacy system and require a prescription. That is very different from so-called "research use only" products, which are sold online outside the pharmacy system entirely, with no prescription, no pharmacist, and no dispensing oversight.
What the Research Shows About the Alternatives
If compounded supply tightens, the main FDA-approved options remain the brand-name semaglutide products and the tirzepatide products (Mounjaro and Zepbound). Tirzepatide has its own substantial trial record. In a trial of adults with obesity, tirzepatide was associated with mean weight reductions ranging from 15.0 percent at the lowest studied dose to 20.9 percent at the highest, versus 3.1 percent for placebo over 72 weeks. As with semaglutide, those are averaged trial findings rather than a guaranteed personal result. Its regulatory status regarding compounding is being handled on a separate track and continues to evolve.
There is also growing attention on the next generation. Retatrutide, an investigational triple-receptor agonist, was associated with dose-dependent weight reductions of up to roughly 24 percent at 48 weeks in a phase-2 obesity trial. That is an early-stage, trial-only compound. It is not FDA-approved, it is not something you can be legally prescribed for weight loss today, and researchers are still studying open questions about weight loss at that magnitude. Treat any online offer of retatrutide with strong skepticism.
A Note on Untested Blends
Some telehealth sellers have marketed semaglutide combined with other peptides or additives that have never been studied together in a clinical trial. Adding an unstudied ingredient to a studied molecule has not been shown to improve outcomes, and it introduces unknowns that neither a seller nor a buyer can account for. When you cannot find a trial that tested the exact combination you are being sold, that absence of evidence is itself the finding. The honest position is straightforward: what has been studied has been studied as single, defined products dispensed through the licensed system.
How to Find Safe, Legal Treatment
If you want to pursue a GLP-1 medication, the safest path runs through a licensed prescriber and a licensed pharmacy, whether that is a brand-name product or a compounded one from a legitimate 503A or 503B facility while that remains permitted. Be wary of anything sold as "research use only," anything with no prescription requirement, and anything promising a specific outcome. To compare providers that operate inside the licensed system, see the provider directory. To understand exactly how the Foundation scores them, including how we weight licensing, transparency, and safety, read how we rate. If you have broader questions about the category, our FAQ covers the common ones.
The Honest Bottom Line
The FDA's underlying concern about manufacturing quality is legitimate, and the affordability problem it leaves behind is also real. Both things are true at once. Nothing in the current rulemaking makes compounded semaglutide vanish overnight, and comment periods and likely legal challenges mean a transitional window rather than a hard stop. Use that window to understand your options through the licensed system rather than the gray market. These medications have been studied, but the studies describe populations and probabilities, not guarantees, and the version that comes with a prescription, a pharmacist, and a verified label is the one with the most oversight behind it.